Influenza vaccines: New developments

Current Opinion in Pharmacology

Volumn 1, Issue 5, 2001, Pages 491-496

  Rimmelzwaan, Guus F ^a   Osterhaus, Albert D M E ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; INFLUENZA VACCINE;

ANIMAL; GENETICS; HUMAN; IMMUNOLOGY; INFLUENZA; METHODOLOGY; PHARMACEUTICS; REVIEW; SYNTHESIS; VIROLOGY;

ANIMAL; HUMAN; INFLUENZA; INFLUENZA VACCINE; TECHNOLOGY, PHARMACEUTICAL; VACCINES, DNA;

EID: 0035487260     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(01)00085-6     Document Type: Review

References (46)

1. Murphy BR, Webster RG: Orthomyxoviruses. In Fields Virology, edn 3. Edited by Fields BN, Knipe DM, Howley PM et al. Philadelphia: Lippincott-Raven Publishers; 1996:1397-1445.
2. Slepushkin VA, Katz JM, Black RA, Gamble WC, Roata PA, Cox NJ: Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 1995, 13:1399-1402.
3. Frace AM, Klimov AI, Rowe T, Black RA, Katz JM: Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 1999, 7:2237-2244.
4. Neirynck S, Deroo T, Saelens X, Vanlanschoot P, Min Jou W, Fiers W: A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat ed 1999, 5:1157-1163.
5. World Health Organization: Recommended composition of influenza virus vaccines for use in the 2000-2001 season. Wkl Epidemiol Rec 2000, 75:61-68.
6. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y: Evolution and ecology of influenza A viruses. Microbiol Rev 1992, 56:152-179.
7. De Jong JC, Claas ECJ, Osterhaus ADME, Webster RG, Lim WL: A pandemic warning? Nature 1997, 389:554.
8. Claas ECJ, Osterhaus ADME, Van Beek R, De Jong JC, Rimmelzwaan GF, Senne DA, Krauss S, Shortridge KF, Webster RG: Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998, 351:472-477.
9. Subbarao K, Klimov A, Katz J, Regnery H, Lim W, Hall H, Perdue M, Swayne D, Bender C, Huang J et al.: Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998, 279:393-396.
10. Lin YP, Shaw M, Gregory V, Cameron K, Lim W, Klimov A, Subbarao K, Guan Y, Krauss S, Shortridge K et al.: Avian to human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proc Natl Acad Sci USA 2000, 97:9654-9658.
11. Nichol KL: Efficacy/ clinical effectiveness of inactivated influenza virus vaccines in adults. In Textbook of Influenza Edited by Nicholson KG, Webster RG, Hay AJ. Oxford: Blackwell Science; 1998:358-372.
12. Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A: ISCOM, a novel structure for antigen presentation of membrane proteins of enveloped viruses. Nature 1984, 308:457-460.
13. Rimmelzwaan GF, Osterhaus ADME: ISCOMs: materials, preparation, antigen delivery and immune response. In Antigen Delivery Systems. Edited by Gander B, Merkle HP, Corradin G. Amsterdam: Harwood Academic Publishers; 1997:123-138.
14. Rimmelzwaan GF, Baars M, Van Beek R, Van Amerongen G, Lövgren K, Claas ECJ, Osterhaus ADME: Induction of protective immunity against influenza in a macaque model: comparison of conventional and ISCOM vaccines. J Gen Virol 1997, 78:757-765.
15. Rimmelzwaan GF, Claas ECJ, Van Amerongen G, De Jong JC, Osterhaus ADME: ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine 1999, 17:1355-1358.
16. Van Binnendijk RS, Van Baalen CA, Poelen MCM, de Vries P, Boes J, Cerundulo V, Osterhaus ADME, UytdeHaag FGCM: Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I and class II-restricted cytotoxic T-cell recognition. J Exp Med 1992, 176:119-126.
17. + cytotoxicT-lymphocytes. Vaccine 2000, 19:514-522.
18. •].
19. •] describe for the first time in man that vaccination with ISCOM-based vaccines induces virus-specific CTL responses.
20. Martin JT: Enhanced immunogenicity of Chiron Biocine adjuvanted influenza vaccine in the elderly. In Options for the Control of Influenza III. Edited by Brown LE, Hampson AW, Webster RG. Amsterdam: Elsevier Science; 1996:647-652.
21. Ott G, Barchfeld GL, Chernoff DD, Radhakrishnan R, Van Hoogevest P, Van Nest G: MF59: design and evaluation of a safe and potent adjuvant for human vaccines. In Vaccine Design: the Subunit and Adjuvant Approach. Edited by Powell MF, Newman MJ. New York: Plenum Press; 1995:277-295.
22. Minutello M, Senatore F, Cechinelli G, Bianchi M, Andreani T, Podda A, Crovari P: Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999, 17:99-104.
23. De Donato S, Granoff D, Minutello M, Lecchi G, Faccini M, Agnello M, Senatore F, Verweij P, Fritzell B, Podda A: Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999, 17:3094-3101.
24. Glück R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ: Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994, 344:160-163.
25. Glück R, Wegmann A: Virosomes, a new liposome-like vaccine delivery system. In Antigen Delivery Systems. Edited by Gander B, Merkle HP, Corradin G. Amsterdam: Harwood Academic Publishers; 1997:101-122.
26. Conne P, Gauthey L, Vernet P, Althaus B, Que JU, Finkel B, Gluck R, Cryz SJ Jr: Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 1997, 15:1675-1679.
27. Keitel WA, Piedra PA: Live cold-adapted, reassortant influenza vaccines (USA). In Textbook of Influenza. Edited by Nicholson KG, Webster RG, Hay AJ. Oxford: Blackwell Science; 1998:373-390.
28. Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Peidra P, Bernstein DI, Hayden FG, Kotloff K, Zangwill K et al.: The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. New Eng J Med 1998, 338:1405-1412.
29. Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, Treanor J, Zangwill K, Hayden FG, Bernstein DI et al.: Correlates of immune protection induced by live, attenuated, cold adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000, 181:1133-1137.
30. Schild GC, Oxford JS, De Jong JC, Webster RG: Evidence for host-cell selection of influenza virus antigenic variants. Nature 1983, 303:706-709.
31. Brands R, Palache AM, Van Scharrenburg GJM: Madin Darby canine kidney (MDCK)-cells for the production of inactivated influenza subunit vaccine. Safety characteristics and clinical results in the elderly. In Options for the Control of Influenza III. Edited by Brown LE, Hampson AW, Webster RG. Amsterdam: Elsevier Science; 1996:683-693.
32. Palache AM, Brands R, Van Scharrenburg GJM: Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized eggs. J Infect Dis 1997, 176:320-323.
33. Wolff JA, Malone RW, Williams P, Chong W, Ascadi G, Jani A, Felgner PL: Direct gene transfer into mouse muscle cells in vivo. Science 1990, 247:1465-1468.
34. Ulmer JB, Donnely JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A et al.: Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259:1745-1749.
35. Robinson HL, Hunt LA, Webster RG: Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 1993, 11:957-960.
36. Donnely JJ, Friedman A, Martinez D, Montgomery DL, Shiver JW, Motzel SL, Ulmer JB, Liu MA: Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1995, 1:583-587.
37. + T-cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol 1998, 72:5648-5653.
38. + T-cells can promote survival and recovery after challenge. Int Immunol 2000, 12:91-101.
39. Fu TM, Guan L, Friedman, Schofield TL, Ulmer JB, Liu MA, Donnely JJ: Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge. J Immunol 1999, 162:4163-4170.
40. Gurunathan S, Klinman DM, Seder RA: DNA vaccines: immunology, application and optimization. Annu Rev Immunol 2000, 18:927-974. This paper provides an excellent and state-of-the-art review of DNA vaccination.
41. Klinman DM, Takeno M, Ichino M, Gu M, Yamshchikov G, Mor G, Conover J: DNA vaccines: safety and efficacy issues. Springer Semin Immunopathol 1997, 19:245-256.
42. Enami M, Luytjes W, Krystal M, Palese P: Introduction of site-specific mutations into the genome of influenza virus. Proc Natl Acad Sci USA 1990, 87:3802-3805.
43. Neumann G, Zobel A, Hobom G: RNA polymerase I-mediated expression of influenza viral RNA molecules. Virology 1994, 202:477-479.
44. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, Hughes M, Perez DR, Donis R, Hoffman E et al.: Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci USA 1999, 96:9345-9350.
45. Hoffman E, Neumann G, Kawaoka Y, Hobom G, Webster RG: A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci USA 2000, 97:6108-6113. This is a very elegant paper in which it is demonstrated that influenza viruses can be generated efficiently from only eight plasmids.
46. Chen D, Endres RL, Erickson CA, Weis KF, McGregor MW, Kawaoka Y, Payne LG: Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice. Nat Med 2000, 6:1187-1190. This article describes a revolutionary vaccination technology based on epidermal needle-free powder delivery of viral antigen. Viral antigens delivered by this technology proved to be more immunogenic than after subcutaneous or intramuscular administration with epidermal immunization. A higher level of protective immunity was also achieved.